Respiratory Case Reports,
Journal Year:
2024,
Volume and Issue:
13(1), P. 20 - 24
Published: Jan. 1, 2024
Pulmonary
mucormycosis
is
a
relatively
rare
disease
that
may
become
more
common
with
the
increasing
number
of
immunocompromised
patients.The
male
case
presented
here,
advanced
retroviral
disease,
persistent
cough
and
acute
respiratory
distress.A
chest
radiograph
computed
tomography
(CT)
thorax
revealed
right
apical
pneumothorax
mass
in
main
bronchus.Flexible
bronchoscopy
an
endobronchial
mass,
occluded
entirely
bronchus.Histopathological
examinations
multiple
biopsies
fungal
bodies
suggestive
mucormycosis.The
patient
was
treated
Posaconazole,
leading
to
complete
clinical
radiological
cure.
Journal of Fungi,
Journal Year:
2024,
Volume and Issue:
10(1), P. 41 - 41
Published: Jan. 4, 2024
Both
Mucorales
and
Gram-negative
rods
(GNRs)
commonly
infect
patients
with
hematological
malignancies
(HM);
however,
their
co-occurrence
is
understudied.
Therefore,
we
retrospectively
reviewed
the
records
of
63
HM
proven
or
probable
sinopulmonary
mucormycosis
at
MD
Anderson
Cancer
Center
(Houston,
Texas)
from
2000-2020.
Seventeen
out
sixty-three
(27.0%)
had
GNRs
(most
Science Translational Medicine,
Journal Year:
2025,
Volume and Issue:
17(789)
Published: March 12, 2025
Mucormycosis
is
a
fungal
infection
caused
by
Mucorales
fungi
that
cause
severe
disease
and
fatality,
especially
in
immunocompromised
individuals.
Although
vaccines
immunotherapeutics
have
been
successful
combating
viral
bacterial
infections,
approved
antifungal
immunotherapies
are
yet
to
be
realized.
To
address
this
gap,
monoclonal
antibodies
targeting
invasive
infections
emerged
as
promising
approach,
particularly
for
patients
who
unlikely
maximally
benefit
from
vaccines.
The
spore
coat
(CotH)
proteins
identified
crucial
invasins
bind
glucose-regulated
protein
78
(GRP78)
integrins
of
host
barrier
cells.
Previously,
we
described
murine
antibody,
anti-CotH
C2,
which
protected
diabetic
ketoacidosis
(DKA)
neutropenic
mice
mucormycosis.
Here,
advanced
the
development
C2
immunoglobulin
G1
(IgG1)
humanizing
it,
establishing
stable
Chinese
hamster
ovary
cell
line
producing
antibody
at
commercial
yields,
carried
out
optimization
upstream
downstream
manufacturing
processes.
resultant
humanized
IgG1
(VX-01)
exhibited
10-fold
increase
binding
affinity
CotH
conferred
comparable
vitro
vivo
efficacy
when
compared
antibody.
mechanism
protection
was
reliant
on
prevention
angioinvasion
enhancing
opsonophagocytic
killing.
VX-01
demonstrated
acceptable
safety
profiles
with
no
detectable
damage
cells
weak
or
moderate
only
cytoplasmic
ex
good
laboratory
practice–human
tissue
cross-reactivity
studies.
Our
studies
warrant
continued
adjunctive
immunotherapy.
Bulletin of the National Research Centre/Bulletin of the National Research Center,
Journal Year:
2025,
Volume and Issue:
49(1)
Published: March 20, 2025
Abstract
Myiasis
is
a
tropical
parasitic
infestation
prevalent
among
individuals
with
poor
living
conditions
and
immunocompromised
states.
We
present
unique
case
of
nasal
oral
myiasis
in
patient
diabetes
mellitus
post-COVID-19
mucormycosis.
Contrary
to
existing
literature,
this
exhibited
well-controlled
mellitus,
maintained
through
regular
follow-ups
strict
medication
adherence.
To
our
knowledge,
controlled
has
not
been
previously
documented.
This
report
may
thus
provide
valuable
insights
for
physicians
evaluating
patients
post-mucormycosis
status,
irrespective
environmental
or
medical
factors.
Our
study
details
the
71-year-old
male
history
who
presented
persistent
dry
cough,
bleeding,
right-sided
facial
pain
swelling,
intermittent
right
temporal
headache.
The
had
known
COVID-19-associated
mucormycosis
undergone
dental
procedure
six
months
prior.
Oral
cavity
examination
revealed
erosion
teeth
on
side,
migrating
maggot
larvae
upper
third
molar
space,
site
previous
extraction.
He
was
managed
conservatively
analgesics
turpentine
oil.
Endoscopic
removal
maggots
attempted,
single
dose
systemic
Ivermectin
given,
prophylactic
antibiotics
were
prescribed.
improved
symptomatically
discharged.
suggests
that
alone
can
be
potential
risk
factor
myiasis,
therefore,
follow-up,
early
diagnosis,
intervention
status
are
necessary.
Tropical Medicine and Infectious Disease,
Journal Year:
2025,
Volume and Issue:
10(4), P. 86 - 86
Published: March 24, 2025
Background/Objectives:
Mucormycosis
is
a
rare
but
life-threatening
fungal
infection,
particularly
in
neonates,
due
to
their
undeveloped
immune
system.
This
systematic
review
aims
analyze
the
risk
factors,
clinical
presentations,
treatments,
and
outcomes
of
neonatal
mucormycosis
reported
between
2004
2024.
Methods:
A
literature
search
was
conducted
PubMed,
Scopus,
Web
Science
following
PRISMA
guidelines.
Only
studies
reporting
cases
neonates
(≤28
days
old)
were
included.
Data
on
features,
diagnostic
methods,
antifungal
therapies,
surgical
interventions,
extracted
analyzed.
Results:
total
44
met
inclusion
criteria,
comprising
61
cases.
The
most
common
presentations
gastrointestinal
(n
=
39),
cutaneous
19),
rhino-orbito-cerebral
2),
disseminated
1).
Diagnosis
primarily
based
histopathology
(93.4%)
culture
(26.2%).
main
treatment
liposomal
amphotericin
B
(63.9%),
often
combined
with
debridement
(60.6%).
Mortality
rates
remained
high
(47.5%),
prematurely
extreme
angioinvasive
disease
or
delayed
diagnosis.
Conclusions:
Neonatal
remains
severe
condition
morbidity
mortality.
Early
diagnosis
through
combination
suspicion
laboratory
confirmation,
along
prompt
therapy
management,
apparently
crucial
for
improving
outcomes.
Further
are
needed
optimize
strategies
improve
survival.
Microorganisms,
Journal Year:
2025,
Volume and Issue:
13(1), P. 55 - 55
Published: Jan. 1, 2025
Background:
Invasive
mucormycosis
(IM)
poses
a
substantial
morbidity
and
mortality
burden
among
immunocompromised
patients.
Objectives:
We
aim
to
compare
the
real-world
effectiveness
safety
of
isavuconazole
with
those
amphotericin
B
in
patients
IM.
Patients
methods:
In
this
observational
cohort
study,
we
enrolled
who
were
diagnosed
IM
treated
either
or
B.
Results:
A
total
106
met
study
criteria.
Of
these,
47
received
isavuconazole,
59
as
primary
treatment.
The
two
cohorts
had
similar
baseline
characteristics,
including
history
malignancy,
use
immunosuppressants,
infection
sites,
pathogens.
group
demonstrated
significantly
greater
incidence
renal
disorders
(p
<
0.001)
hypokalemia
than
group.
proportion
salvage
therapy
was
(42%
vs.
6%,
p
0.001).
Eighteen
discontinued
treatment
because
adverse
events,
whereas
no
events.
significant
difference
therapeutic
response
between
groups
noted
=
0.013),
higher
failure
rate
(68%
36%,
However,
there
differences
all-cause
mucormycosis-attributable
rates
groups.
Conclusions:
Isavuconazole
outperformed
first-line
option
for
terms
its
clinical
safety.
Dermatopathology,
Journal Year:
2025,
Volume and Issue:
12(1), P. 2 - 2
Published: Jan. 16, 2025
We
present
the
case
of
a
60-year-old
immunocompromised
man
who
presented
with
two
pruritic
pink–red
indurated
nodules
overlying
scale
and
focal
areas
ulceration
on
his
left
dorsal
medial
forearm,
which
evolved
over
2-month
period.
The
pathology
showed
numerous
fungal
hyphae
that
were
pauci-septate
various
branched
angles
variable
hyphal
thickness.
Fungal
cultures
grew
Rhizopus
species
universal
PCR
detected
oryzae
complex.
Based
clinicopathologic
correlation,
diagnosis
cutaneous
mucormycosis
was
made.
Cutaneous
is
an
aggressive
infection
Mucorales
family
occurring
after
inoculation
spores
in
disrupted
skin.
It
usually
presents
as
necrotic
eschar
but
can
also
cellulitis
evolves
into
ulcer.
A
prompt
critical
for
effective
management
mucormycosis.
treatment
includes
immediate
systemic
amphotericin
B
surgical
debridement
regions.
Given
wide
range
presenting
symptoms,
clinical
suspicion
this
emergent
condition
must
remain
high
diabetic
patients.
International Journal of Molecular Sciences,
Journal Year:
2025,
Volume and Issue:
26(6), P. 2494 - 2494
Published: March 11, 2025
Various
species
of
fungi
can
be
detected
in
the
environment
and
within
human
body,
many
which
may
become
pathogenic
under
specific
conditions,
leading
to
various
forms
fungal
infections.
Antimicrobial
peptides
(AMPs)
are
evolutionarily
ancient
components
immune
response
that
quickly
induced
infections
with
pathogens
almost
all
tissues.
There
is
a
wide
range
AMP
classes
humans,
exhibit
broad-spectrum
antimicrobial
function.
This
review
provides
comprehensive
overview
mechanisms
action
AMPs,
their
distribution
antifungal
activity
against
both
common
rare
clinical
pathogens.
It
also
discusses
current
research
status
promising
novel
strategies,
highlighting
challenges
must
overcome
development
these
therapies.
The
hope
peptides,
as
class
agents,
will
soon
progress
through
large-scale
trials
implemented
practice,
offering
new
treatment
options
for
patients
suffering
from